TrialLancet (London, England)2021

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Denis Y Logunov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.